Monoclonal Antibody News and Research

RSS
Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.
Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

Lpath receives NIH SBIR grant to investigate effect of Lpathomab compound on diabetic neuropathy

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

arGEN-X and Shire achieve milestone in SIMPLE Antibody R&D collaboration

Second edition of Antibodies: An essential resource for molecular biology, immunology, and cell culture lab

Second edition of Antibodies: An essential resource for molecular biology, immunology, and cell culture lab

First clinical trials to diagnose and treat Alzheimer’s disease

First clinical trials to diagnose and treat Alzheimer’s disease

Wayne State University initiates groundbreaking multiple sclerosis study

Wayne State University initiates groundbreaking multiple sclerosis study

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

arGEN-X announces CTA filing of Phase Ib cancer study with ARGX-111

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

arGEN-X generates potent antibody antagonists of Nav1.7 using SIMPLE Antibody technology

Paragon Bioservices awarded 2013 CMO Leadership Award for Quality and Reliability

Paragon Bioservices awarded 2013 CMO Leadership Award for Quality and Reliability

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Hospira announces EC approval of Inflectra, Europe's first biosimilar mAb therapy

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

Pharmathene presents new data from SparVax anthrax vaccine program at 2013 Bacillus conference

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

FDA grants Priority Review status to Takeda's investigational drug vedolizumab for ulcerative colitis

UCLA researchers receives $13M Early Translational grants to advance innovative discoveries using stem cells

UCLA researchers receives $13M Early Translational grants to advance innovative discoveries using stem cells

Stem cell researchers receive Early Translational research awards from CIRM

Stem cell researchers receive Early Translational research awards from CIRM

CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

CST introduces HER3 antibody for studying HER2-mediated breast, lung and ovarian tumors

FDA grants Priority Review designation to sNDA for Nexavar tablets

FDA grants Priority Review designation to sNDA for Nexavar tablets

Powerful new option for treating vasculitis

Powerful new option for treating vasculitis

Laureate Biopharma collaborates with Dyax to develop new treatment candidate for HAE

Laureate Biopharma collaborates with Dyax to develop new treatment candidate for HAE

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

Immune Pharmaceuticals announces completion of merger with EpiCept Corporation

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.